ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Pericardial Effusion Tamponade Echocardiography

Mark Rosen

Cardiomyopathies: 2024 Wrap Up

Cardiology 2024 Year in Review

A. Masri

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

MUSC Cardiology

R. Mentz

Echocardiographic Essentials: From Screening to Device Implantation-…

Scottsdale Interventional Forum 2015

G. Gellert

What is the Gold Standard for Non-Invasive Cardiac Stress Testing

Complex Interventional Cardiovascular Therapy (CICT) 2014

M. Bell

PET Imagining in Cardiac Amyloidosis

NYU Langone

S. Dorbala

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

AHA 2022 Conference Coverage

R. Mentz

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

Michelle Kittleson

SGLT2 Inhibition in 2024: Use in Heart Failure and Mechanism of Acti…

28th Annual Heart Failure 2024: An Update on Therapy

M. Packer

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

HFpEF in Women

Scripps Health

B. Borlaug

Echocardiography: Back to the Basics

Fahad Alhabshan

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

Learning from the Echocardiographer: A Review of Degenerative, Funct…

Scottsdale Interventional Forum 2016

R. Burke

Using Cardiac MRI to Assess Progression and Treatment Response

The France Foundation

D. Kwon

Cardiotoxicity: Anthracyclines

Scripps Health

M. Davis

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

UCLA Health

D. Vucicevic

TEE Follow Up After WATCHMAN Implantation

Congenital and Structural Interventions